Article info

PDF

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)

Authors

  1. Correspondence to Dr Juliette Sheridan, Centre for Colorectal Disease, St. Vincent’s University Hospital, School of Medicine, UCD, Dublin 4, Ireland; j.sheridan{at}st-vincents.ie
View Full Text

Citation

Sheridan J, Coe CA, Doran P, et al
Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)

Publication history

  • Received August 22, 2017
  • Revised October 12, 2017
  • Accepted October 17, 2017
  • First published January 11, 2018.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.